search
Back to results

IT-system Development for Reaching Cervix Cancer Screening Non-attenders

Primary Purpose

Human Papillomavirus DNA Tests, Cervical Cancer

Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Cobas PCR Female swab sample Packet
Routine practice
Sponsored by
Karolinska Institutet
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Human Papillomavirus DNA Tests focused on measuring participation, self sampling, Screening

Eligibility Criteria

33 Years - 60 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Non-participants in cervical cancer screening during a 10 year period

Exclusion Criteria:

  • Active refusers

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm 4

    Arm Type

    Active Comparator

    Active Comparator

    Active Comparator

    Placebo Comparator

    Arm Label

    HPV self sampling test sent

    HPV self sampling test ordered

    Nurse navigator contact

    Control

    Arm Description

    A Cobas PCR (polymerase chain reaction) Female swab sample Packet will be sent directly to women with a study invitation letter and instructions. Response rate will be measured.

    An invitation to order a Cobas PCR Female swab sample Packet through an online application will be sent. Response rates will be measured.

    An invitation to call the coordinating midwife with questions and concerns regarding screening will be sent. The coordinating midwife can help the participant order a Cobas PCR Female swab sample Packet or book a standard screening visit, if desired. Response rates will be measured

    The standard, annual renewed invitation to cervical screening will be sent (control, routine practice). Response rate will be measured as a baseline.

    Outcomes

    Primary Outcome Measures

    Proportion of women responding (either by and HPV test or a Pap test)
    Participation rate in screening

    Secondary Outcome Measures

    Full Information

    First Posted
    March 13, 2016
    Last Updated
    September 30, 2020
    Sponsor
    Karolinska Institutet
    Collaborators
    Regional Cancer Centre Stockholm Gotland
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02750124
    Brief Title
    IT-system Development for Reaching Cervix Cancer Screening Non-attenders
    Official Title
    IT-system Development for Individualization of Cervix Cancer Screening and Implementation of New Strategies to Reach Non-attenders
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    September 2020
    Overall Recruitment Status
    Unknown status
    Study Start Date
    March 14, 2016 (Actual)
    Primary Completion Date
    December 31, 2016 (Actual)
    Study Completion Date
    December 2021 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Karolinska Institutet
    Collaborators
    Regional Cancer Centre Stockholm Gotland

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    The main purpose is to develop and test an IT-infrastructure to provide more individualized ways of inviting and reaching women who have not participated, despite having been invited with annual reminders, in cervix cancer screening program during a ten year period.
    Detailed Description
    BACKGROUND Non-participation in the screening program is the main risk factor for cervical cancer (Andrae et al JNCI, 2008). Therefore it is important to reduce barriers to screening and facilitate participation in the screening program for cervical cancer. Offering self-sampling kits for human papillomavirus (HPV) testing has been examined in several research studies as a way to reach women who have not responded to screening invitations. Results from a population-based, randomized study in western Sweden concluded that by offering HPV self-sampling kits to screening non-attendees, 17% of cervical cancer cases could be avoided. Offering self-sampling kits to women who have not attended screening in the organized program, can lead to greater participation without substantial increases in the overall health care costs. While there is a growing body of evidence supporting the use of self-sampling, it is unclear how this strategy can be implemented effectively in the context of an organized screening program. An alternative is to offer women the chance to speak with a coordinating midwife who can answer questions and address concerns regarding screening. It is unclear how the results of different research studies should be put into practical use within an organized screening program. Currently, women who have not attended screening are sent an annual reminder invitation. We want to examine whether these alternative strategies (self-sampling and contact with a midwife) may work as well, or better, than current strategy of reminder invitations to non-attenders. AIM The aim of this randomized health services study is therefore both to test the feasibility of providing alternative strategies instead of the customary reminder invitations to women in Stockholm (so-called feasibility study, primary aim), and whether such strategies will increase overall participation in screening (secondary aim). STUDY DESIGN AND METHODOLOGY A new IT infrastructure for ordering a self-sampling kit has been developed by LabMed, KI. This in conjunction with the screening database, will be used to identify and invite women who are long-term non-participants in cervical screening. Women who have not participated for ten years, despite annual reminder invitations, will be identified and randomized to one of four strategies. A validated HPV self-sampling kit will be sent directly to women with a study invitation letter and instructions. An invitation to order an HPV self-sampling kit through an online application will be sent. An invitation to call the coordinating midwife with questions and concerns regarding screening will be sent. The standard annual reminder invitation will be sent (control, routine practice) Women who choose to participate will be sampled and monitored according to the standards of care in the regional cancer screening program. HPV-positive women will be followed by colposcopy and biopsy according to standard clinical guidelines. Women will be invited over the course of 3 months. All letters will be printed in advance with pre-marked dates. Batches will be sent out weekly and checked against changes in the population registry data (for individuals that have moved, taken a smear, died, or unregistered, invitation letters will be sorted out and those individuals marked in the database). 2 Notation and abbreviations PNR = person nummer, personal ID number 3 Study population 3.1 Inclusion criteria Women who have lived in Stockholm for the past 10 years and have been sent annual reminder at least once per year for 10 years without attending screening. Specific selection process: Include women without an "H-prov" on record for the past 10 years Include women have actively been sent a reminder invitation (invitation type=1) during 10 years time. In other words, resident in Stockholm for the past 10 years. Include women over the age of 33 3.2 Exclusion criteria Women who have opted out of the screening program Hysterectomized Return to sender Changed PNR Women who are marked as Expired=1. Women who have reason marked for being unregistered but are not marked as is unregistered=1. Women who are due to receive their reminder invitation in the next 3 months 4 Statistical analyses Selection of the study population Randomization A random selection of 8000 women will be chosen from all women meeting the study inclusion criteria. These 8000 women will be randomized to the 4 study arms (age-stratified 30-50 and 51-60). The selection of the study population and the randomization to study arms will be carried out by Anna Stoltenberg, Statistician at RCC and outside of the study group 1. Follow-up - study end date 2016-12-31

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Human Papillomavirus DNA Tests, Cervical Cancer
    Keywords
    participation, self sampling, Screening

    7. Study Design

    Primary Purpose
    Prevention
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    8000 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    HPV self sampling test sent
    Arm Type
    Active Comparator
    Arm Description
    A Cobas PCR (polymerase chain reaction) Female swab sample Packet will be sent directly to women with a study invitation letter and instructions. Response rate will be measured.
    Arm Title
    HPV self sampling test ordered
    Arm Type
    Active Comparator
    Arm Description
    An invitation to order a Cobas PCR Female swab sample Packet through an online application will be sent. Response rates will be measured.
    Arm Title
    Nurse navigator contact
    Arm Type
    Active Comparator
    Arm Description
    An invitation to call the coordinating midwife with questions and concerns regarding screening will be sent. The coordinating midwife can help the participant order a Cobas PCR Female swab sample Packet or book a standard screening visit, if desired. Response rates will be measured
    Arm Title
    Control
    Arm Type
    Placebo Comparator
    Arm Description
    The standard, annual renewed invitation to cervical screening will be sent (control, routine practice). Response rate will be measured as a baseline.
    Intervention Type
    Device
    Intervention Name(s)
    Cobas PCR Female swab sample Packet
    Intervention Description
    The cobas® PCR Female Swab Sample Kit is used to collect and transport vaginal swab specimens self-collected.
    Intervention Type
    Other
    Intervention Name(s)
    Routine practice
    Intervention Description
    The standard, annual renewed invitation to cervical screening.
    Primary Outcome Measure Information:
    Title
    Proportion of women responding (either by and HPV test or a Pap test)
    Description
    Participation rate in screening
    Time Frame
    From recruitment until end of study on December 31st 2016 (average 8 months)

    10. Eligibility

    Sex
    Female
    Minimum Age & Unit of Time
    33 Years
    Maximum Age & Unit of Time
    60 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Non-participants in cervical cancer screening during a 10 year period Exclusion Criteria: Active refusers
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Joakim Dillner, MD
    Organizational Affiliation
    Karolinska Institutet
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    Undecided
    IPD Sharing Plan Description
    Our intention is to share data, but a plan for how this will be done in practise has not been written.
    Citations:
    PubMed Identifier
    31032904
    Citation
    Elfstrom KM, Sundstrom K, Andersson S, Bzhalava Z, Carlsten Thor A, Gzoul Z, Ohman D, Lamin H, Eklund C, Dillner J, Tornberg S. Increasing participation in cervical screening by targeting long-term nonattenders: Randomized health services study. Int J Cancer. 2019 Dec 1;145(11):3033-3039. doi: 10.1002/ijc.32374. Epub 2019 May 10.
    Results Reference
    result
    PubMed Identifier
    31522376
    Citation
    Andersson S, Belkic K, Mints M, Ostensson E. Acceptance of Self-Sampling Among Long-Term Cervical Screening Non-Attenders with HPV-Positive Results: Promising Opportunity for Specific Cancer Education. J Cancer Educ. 2021 Feb;36(1):126-133. doi: 10.1007/s13187-019-01608-0.
    Results Reference
    derived

    Learn more about this trial

    IT-system Development for Reaching Cervix Cancer Screening Non-attenders

    We'll reach out to this number within 24 hrs